Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286).
Marina B KleinJim YoungDavid Ortiz-ParedesShouao WangSharon WalmsleyAlexander WongValérie Martel-LaferrièreNeora PickBrian ConwayJonathan AngelJean-Guy BarilChris FraserBertrand LebouchéDarrell Hoi-San TanRoger SandreSylvie TrottierHansi PeirisJayamarx JayaramanJoel Singernull nullPublished in: Patient preference and adherence (2022)
Results of our trial are consistent with a slight improvement in viral suppression in a vulnerable population when a single tablet regimen is combined with patient-level adherence support. Beyond treatment simplicity and tolerability, tailored interventions addressing stigma and social determinants of health are still needed. The numerous challenges we encountered illustrate how randomised trials may not be the best approach for assessing adherence interventions in vulnerable populations.
Keyphrases
- open label
- phase iii
- phase ii
- clinical trial
- study protocol
- double blind
- placebo controlled
- phase ii study
- hiv infected patients
- mental health
- physical activity
- randomized controlled trial
- antiretroviral therapy
- healthcare
- public health
- hiv aids
- squamous cell carcinoma
- sars cov
- hiv infected
- depressive symptoms
- radiation therapy
- social support
- case report
- climate change
- skeletal muscle
- smoking cessation
- insulin resistance
- cross sectional